MANUSCRIPT

Title: Use of undetectable viral load to improve population-based survey estimates of known HIV-positive status and antiretroviral treatment coverage in Kenya

Running head: Adjusting survey estimates with viral load

Peter W. Young[1,§], Emily Zielinski-Gutierrez[1], Joyce Wamicwe[2], Irene Mukui[2], Andrea A. Kim[3], Anthony Waruru[1], Clement Zeh[3], Mirjam E. Kretzschmar[4,5], Kevin M. De Cock[1]

[1] Division of Global HIV & TB, U.S. Centers for Disease Control and Prevention, Nairobi, Kenya

[2] National AIDS & STI Control Programme, Ministry of Health, Kenya

[3] Division of Global HIV & TB, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA

[4] Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht (UMCU), Utrecht, the Netherlands

[5] Centre for Infectious Disease Control, National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands

Keywords: HIV surveillance, antiretroviral treatment, population surveys, biomarkers, Kenya

[§] Corresponding author: Peter Wesley Young

PO Box 606
Village Market
Nairobi, Kenya 00601
Email: pyoung1@cdc.gov phone: +254728608673

Attribution of support:

The 2012 Kenya AIDS Indicator Survey has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC) under the terms of #PS001805, GH000069, and PS001814. The survey was also funded in part by support from the Global Fund, World Bank, and the Joint United Nations Programme on HIV/AIDS.

A portion of this analysis has been accepted as an abstract to the 2019 International AIDS Society (IAS) conference.

Disclaimer: The findings and conclusions in this manuscript are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention and other funding institutions.

Abstract

Introduction: Underreporting of prior HIV diagnosis and antiretroviral therapy (ART) use based on self-report is well-documented in national surveys. Antiretroviral (ARV) testing has been used to improve survey estimates, by reclassifying respondents with ARVs detected in blood as previously-diagnosed and on ART. Viral load testing, which is more affordable and more routinely available than ARV testing, is also an indicator of ART use. We examined the impact of adjusting estimated knowledge of HIV-positive status and antiretroviral therapy (ART) use based on self-report with biomarkers for antiretroviral (ARV) drug detection and undetectable viral load (UVL).

Methods: We reclassified HIV-positive participants aged 15-64 years in the 2012 Kenya AIDS Indicator Survey (KAIS) that were unaware of their HIV-positive status by self-report as aware and on ART if either ARVs were detected or viral load was undetectable (<550 copies/mL) on dried blood spots. We compared self-report to adjustments for ARVs measurement, UVL, or both. We calculated measures of accuracy for UVL and UVL & ARV-adjusted versions of knowledge of status and ART use versus ARV-adjusted self-report as a reference standard.

Results: Among 235 of 648 HIV-positive respondents with UVL, self-reported status was: 65 unaware (28.7%), 25 aware, not on ART (9.9%) and 145 aware, on ART (61.3%). Treatment coverage among all HIV-positive respondents increased from 31.8% for self-report to 42.5% [95% confidence interval (CI) 37.4-47.8] based on ARV detection alone, to 42.8% (95% CI 37.9-47.8) when ARV-adjusted, 46.2% (95% CI 41.3-51.1) when UVL-adjusted and 48.8% (95% CI 43.9-53.8) when adjusted for ARV and UVL. Awareness of positive status increased from 46.9% for self-report to 56.2% (95% CI 50.7-61.6) when ARV-adjusted, 57.5% (95% CI 51.9-63.0) when UVL-adjusted, and 59.8% (95% CI 54.2-65.1) when adjusted for ARV and UVL. Sensitivity and specificity of UVL-adjusted known HIV-positive status were

95.8% and 91.3%, and of UVL-adjusted ART use were 93.0% and 88.8% respectively, versus ARV-adjusted self-report.

Conclusions: Undetectable viral load may be a useful adjunct or alternative to ARV detection for adjusting knowledge of status and ART use indicators in population-based surveys.

Introduction

The HIV cascade of care, can be described by how many HIV-infected persons know their status, how many who know their status are on antiretroviral therapy (ART), and how many on ART are virally suppressed. These indicators are used to monitor progress towards controlling the HIV epidemic. Since the 2007 Kenya AIDS Indicator Survey (KAIS), HIV seroprevalence surveys have often included questions on knowledge of HIV status and antiretroviral (ARV) use among HIV-infected respondents, as well as treatment-related biomarkers such as viral load (VL) [1–3]. However, HIV continues to be a highly stigmatized disease in spite of rapid scale up of life-saving treatment [4,5], therefore self-reported knowledge of status and ART can be subject to either positive or negative social desirability bias in some respondents. Some respondents may also have inaccurate understanding and recall of detailed questions about their HIV testing and care histories [6].

Recent surveys have used ARV testing to improve interpretation of self-reported HIV cascade indicators by reclassifying respondents with ARVs detected in their blood as being previously diagnosed and on ART [7,8]. In the 2012 KAIS 46.9% [95% confidence interval (CI) 41.3–52.4] of HIV-infected respondents self-reported that they were aware of their HIV-positive status, but ARVs were also detected in 21.0% of those not reporting prior HIV diagnosis and 19.3% of those reporting no previous HIV test. Younger age and higher household wealth index were independently associated with undisclosed ART [7]. After reclassifying those who had detectable ARVs in their blood knowledge of HIV-positive status rose to 56.2% (95% CI 50.7–61.7). Self-reported population ART coverage was 31.8% (95% CI 27.1–36.5); after adjusting for ARV detection it rose to 42.8% (95% CI 37.9–

47.8) [7]. These increased estimates of both knowledge of HIV-positive status and ART coverage underscore the potential utility of biomarker adjustments on self-reported indicators in population-based surveys.

Antiretroviral testing is both highly sensitive and specific for detection of ARVs in blood [9,10], thus false-positive results are unlikely and anyone testing positive for both HIV and ARVs is likely to be on treatment and previously diagnosed with HIV infection. A negative ARV test in an HIV-positive respondent however may reflect either ARV non-use, poor recent adherence, or non-correspondence between drugs in test panel and those in use in the population. Thus, surveys that include ARV testing usually define ART use as either self-reported use of ART or detection of ARVs in the blood. Antiretroviral testing is also relatively complex, expensive both in terms of up-front investment and ongoing operational costs, and not widely available within national public health laboratories in high-HIV-burden countries.

Viral load monitoring has become a routine part of clinical HIV care given its utility in identifying treatment failure, defined as having a persistent viral load ≥ 1000 copies/mL among patients on treatment [11]. UNAIDS defines viral suppression for surveillance and reporting purposes as VL < 1000 copies/mL [12]. Viral load testing platforms have been implemented widely in high-HIV-burden countries at reasonable cost (9.40 US Dollars per test [13]). The Abbott M2000 Real-Time HIV-1 Assay (Abbott Laboratories, Abbott Park, Illinois, USA) platform used in the KAIS 2012 survey has sensitivity 93.9% (95% CI 88.8–97.2) and specificity of 88.0% (95% CI 82.2–92.4) for viral detection at a cutoff of 550 copies/mL in dried blood spots (DBS) [14]. While undetectable viral load (UVL) is generally indicative of viral suppression due to treatment, the presence of elite controllers (EC) who have UVL in the absence of treatment could confound its use as a proxy for ART use. The prevalence of EC in the population is not well characterized: in US and European cohorts they are believed to represent 0.15–1.5% of the HIV-infected population [15], while in East African settings similarly-low prevalence of EC has been observed [16,17], though in one cross-sectional population-based assessment in Uganda 10% of participants with undetectable viral load were not on ART according to self-report, ARV testing and chart review, raising the possibility of higher prevalence of elite control in this population [18].

Although both ARV detection and UVL have the potential to correct for under-reporting of known HIV status and ART use among HIV-positive survey participants, the converse is not true. Survey respondents on ART can be non-adherent to their medication leading to undetectable ARV blood levels. Similarly, patients on treatment may still have detectable viral load, either due to suboptimal drug concentrations, recent treatment initiation, or treatment failure due to drug resistance.

A better understanding of the relationship between UVL and ARV detection is required to assess the utility of VL testing as an alternate or adjunct biomarker for use in survey adjustment. In order to explore the impact of alternative approaches to adjusting HIV diagnosis and ART coverage estimates, we looked at whether adjusting the HIV cascade using a measure of viral load would achieve similar results to adjustments based on detection of ARVs, as well as the impact of simultaneously adjusting based on both biomarkers.

Methods

The 2012 KAIS was a national household survey that included behavioral questions including self-reported HIV and ART status as well as collection of venous blood from which DBS were prepared by field teams and plasma separated and shipped for HIV testing at a national laboratory [2]. After participating in other survey procedures, participants were offered rapid HIV testing by trained HIV counselors in their homes with immediate return of results based on national HIV testing guidelines [19]. Participants testing positive for HIV at the central lab were subsequently tested for viral load using the Abbott M2000 platform on DBS, and DBS were also shipped to the University of Cape Town for ARV testing. Antiretrovirals were considered present if one or more of efavirenz, nevirapine, lopinavir or lamivudine were detected by liquid chromatography tandem mass spectrometry (limit of detection 0.02 µg/mL); these drugs were selected to cover first- and second-line regimens in use in Kenya at the time of the survey [7,20,21].

We retrospectively re-analyzed survey data to compare self-reported and biomarker-adjusted versions of knowledge of status and ART use among HIV-infected respondents aged 15-64 years.

Measures

Self-reported HIV status among respondents testing HIV-positive in the survey was defined as 'unaware' of their HIV-positive status, 'aware, on ART', or 'aware, not on ART'. Participants with confirmed HIV-positive status who self-reported being HIV-positive during the interview were categorized as 'aware' of their HIV-positive status; all other HIV-positive respondents, including those that refused to answer, were categorized as 'unaware' of their HIV-positive status. HIV-positive respondents categorized as 'aware' who further responded yes to both the question 'have you ever taken ARVs, that is, antiretroviral medication, to treat your HIV infection' and 'are you currently taking ARVs, that is, antiretroviral medications daily?' were re-categorized as 'aware, on ART', otherwise as 'aware, not on ART'.

We defined UVL as having a viral load <550 copies/mL on dried blood spots, the limit of detection for the assay used in the study. To calculate UVL-adjusted status, we updated the status for those respondents categorized as 'unaware' or 'aware, not on ART' with undetectable viral load to 'aware, on ART'. Similarly, ARV-adjusted status was calculated by updating the status for respondents with ARVs detected in blood to 'aware, on ART'. For either case, the status for respondents with missing biomarker results were not updated.

We tabulated versions of population ART coverage based on 1) self-report alone, 2) ARV detection alone, 3) self-report adjusted for ARVs, 4) self-report adjusted for UVL and 5) self-report adjusted for both ARVs and UVL. We explored differences in these indicators by age, sex, marital status, educational attainment and mobility. We also tabulated self-reported, ARV- and UVL-adjusted versions of known HIV-positive status, ART coverage among those who knew their HIV-positive status and viral suppression (defined as having <1000 copies/mL in blood) among those on ART, the indicators for which the Joint United Nations Programme on HIV/AIDS (UNAIDS) has set Fast-track targets to ensure 90% of people living with HIV (PLHIV) know their HIV status, 90% of those who know their status are on treatment, and 90% of those on treatment are virally suppressed by 2020 [22]. ARV-only estimates are not presented for the cascade as this adjustment is only meaningful for measures of ART coverage. We calculated measures of accuracy for UVL and UVL & ARV-adjusted versions of knowledge of status and ART use versus ARV-adjusted as a reference standard. Results were analyzed in R version 3.5.0 [23] using the survey package [24]. Resulting indicators were adjusted and weighted to account for the complex survey

design, except for measures of accuracy. Wald confidence intervals for survey indicators were calculated on the logarithmic scale and transformed to probability scale using the 'logit' method of the svyciprop function in R; confidence intervals previously reported by Kim et al were calculated on the probability scale). Wilson score confidence intervals are reported for measures of accuracy.

Ethical approval

The 2012 KAIS was approved by the Committee on Human Research of the University of California, San Francisco, the Institutional Review Board of the U.S. Centers for Disease Control (CDC) in Atlanta, GA, USA (protocol #6189) and the Ethical Review Committee of the Kenya Medical Research Institute.

Results

In KAIS 2012, among 648 HIV-infected respondents, self-reported status was 'unaware' among 343 (53.1%), 'aware, not on ART' among 100 (15.1%), and 'aware, on ART' among 205 (31.8%) (Table 1). Status varied by age and sex: 120 (62.0%) men versus 223 (47.8%) women were unaware of their HIV-positive status by self-report, and 59 (82.0%) 15–24 year olds versus 121 (58.9%) 25–34 year olds were unaware of their HIV-positive status by self-report. Only 6 (7.1%) of 15–24 year olds were aware and on ART compared with 47 (48.0%) of 50–64 year olds. Among those with undetectable viral load, 65 (28.7%) were unaware of their HIV-positive status by self-report, compared with 55 (25.2%) of those with ARVs detected (Table 1). Of those with UVL and unaware of their HIV-positive status by self-report, 40 also had ARVs detected in blood (Supplemental Table S1).

Antiretroviral treatment coverage among all HIV-infected increased from 31.8% (95% CI 27.3–36.6) based on self-report to 42.5% (95% CI 37.4–47.8) based on ARV detection alone, to 42.8% (95% CI 37.9–47.8) when combining self-report and ARV detection, to 46.2% (95% CI 41.3–51.1) when combining self-report and UVL, and finally to 48.8% (95% CI 43.9–53.8) with self-report, UVL and ARVs combined (Table 2). Changes in ART coverage were fairly consistent across demographic characteristics, typically increasing when measured by ARV only versus self-report only, and increasing further when combining both indicators. The 15–24 year age group saw an increase from 7.1% when self-reported only to 21.6% based on ARVs only and 20.7% when based on self-

report and ARVs combined, and up to 29.9% when combining both indicators. The single or never married group also saw larger increases in ART coverage when adjusting. The 25–34 year age group had smaller increases due to adjustments than other groups, as did the no education category (Table SX).

When reviewing the cascade of HIV care based on the UNAIDS Fast-Track 90-90-90 indicators, knowledge of status increased from 46.9% (95% CI 41.4–52.4) based on self-report to 56.2% (95% CI 50.7–61.6) when adjusting with ARVs, to 57.5% (95% CI 51.9–63.0) when adjusting for UVL, and to 59.8% (95% CI 54.2–65.1) when adjusting for both ARV and UVL (Table 3 & Figure 1). Antiretroviral treatment among those previously-diagnosed (the second 90 cascade indicator) increased from 67.9% (95% CI 61.7–73.8) when the numerator and denominator were based on self-report to 76.2% (95% CI 70.3–81.2) when numerator and denominator were ARV-adjusted, to 80.2% (95% CI 75.2–84.4) when UVL-adjusted, and finally to 81.7% (95% CI 76.8–85.8) when adjusted for both ARV and UVL. Viral suppression among those on ART (the third 90 cascade indicator) was 75.4% (95% CI 68.4–81.2) when the denominator was based on self-report alone, 75.6% (95% CI 69.5–80.8) when based on self-report and ARV detection, 83.1 (95% CI 78.2–87.1) when adjusted for UVL, and to 78.6% (95% CI 73.4–83.1) wen adjusting for both ARV and UVL. The youngest age group also saw the biggest impact of adjustment versus self-report in the cascade indicators in both relative and absolute terms.

When using the ARV-adjusted indicator as a reference standard for knowledge of HIV-positive status, the sensitivity of UVL-adjusted self-reported knowledge of HIV infection was 95.8% (95% CI 93.7–97.9), and specificity was 91.3% (95% CI 88.1–94.6). Positive predictive value was 93.2% while negative predictive value was 94.6% (Table 4). When using the ARV-adjusted indicator as a reference standard for ART coverage, sensitivity of UVL-adjusted self-report was 93.0% (95% CI 89.9–96.0) and specificity was 88.8% (95% CI 85.7–92.0). Positive predictive value was 85.8% and negative predictive value was 94.6% (Table 5).

We repeated the analysis excluding the respondents for whom either the ARV or UVL biomarkers were not available from all adjustments, findings were generally similar (Supplemental Table S2). However, the differences between ARV adjustments and UVL adjustments were less pronounced. The 15–24 year age group had a disproportionate number of missing ARV testing results (16 out of 75, which was about double the

proportion seen in the remaining age groups) which may have contributed to a lower adjustment based on ARVs than on UVL in this age group.

Discussion

In KAIS 2012, UVL-adjusted point estimates were quite similar to, but slightly greater than ARV-adjusted estimates of knowledge of status and ART coverage. This suggests that adjustment with UVL might have been adequate and would be preferable to making no adjustment at all, as the UVL-adjusted indicators are closer to the ARV-adjusted indicators than they are to self-reported status alone. When measuring ART coverage, all of the adjusted estimates (ARV only, UVL only, and ARV/UVL combined) had overlapping confidence intervals, but appear to be significantly higher than estimates based on self-report alone. The change in estimates when adjusting by ARVs and UVL were similar across demographic groups, but 15–24 year olds did see a larger additional increase when adjusting by UVL. This may indicate poor recent adherence in this group leading to non-detection of the ARV biomarker but undetectable viral load (<550 copies/mL in this study). Li et al found that 37% of patients still had a viral load <200 copies/mL four weeks after interrupting ART, with a lower proportion still suppressed among patients on protease inhibitor-based regimens compared with non-nucleoside reverse transcriptase inhibitor-based regimens [25]. Many ARVs reach undetectable levels in blood within several days of treatment interruption, with the exception of efavirenz which can take 12–28 days to reach undetectable levels [7,9,26], thus in populations with poor adherence or high rates of treatment interruption, adjusting based on UVL may result in higher estimated ART coverage than measures incorporating ARV detection. Never married respondents also had larger increases in ART coverage when adjusted, however this was likely due to confounding with age, as never-married persons tend to be younger.

In this analysis we treated combined self-report or ARV detection as a reference standard as it appears to be the current preferred approach for adjusting knowledge of status and ART coverage in population-based surveys [27]. Compared with this standard, combined self-report or UVL performed well with a sensitivity of 95.8% and specificity of 91.3% for knowledge of status, and sensitivity of 93.0% and specificity of 88.8% for ART coverage in

this study. The performance of UVL for adjusting ART use will depend on the prevalence of UVL in the population on HIV treatment. In populations with effective ART programs with high rates of viral suppression in the treated population, it may be a relatively sensitive marker for ART use; however, in populations with poor treatment outcomes a larger proportion of patients on treatment would not have UVL.

The prevalence of elite controllers has not been established in Kenya, hence it is not possible to quantify their influence on the UVL-adjusted estimates, but given the similarity between UVL-adjusted and ARV-adjusted estimates, their practical impact was limited in this survey. Although it is possible that estimates adjusted with both the UVL and ARV biomarkers simultaneously may in fact be closest to true population prevalence of the indicators of interest, without better data on prevalence of elite controllers in this population it seems more conservative to use one or the other markers, but not both. In settings with ample evidence of low prevalence of elite control, or where population high ART coverage and immediate treatment initiation means even elite controllers are likely to be on treatment, using the combined indicator would likely represent the most sensitive approach to estimating population-based knowledge of status and ART coverage.

This analysis was subject to several limitations. While adjusting for biomarkers associated with ARV exposure from a single time-point can account for misreporting of status among those on ART, it cannot account for those who misreport their knowledge of HIV-positive status but are not currently on treatment, or those who may be on treatment but transiently non-adherent to medications. This analysis was based on data from a single country with low ART coverage (43.5%, 95% CI 38.5–48.4) and viral suppression among those on treatment (73.9%, 95% CI 67.8–80.0) at the time of the survey compared with current program coverage. The UVL adjustment may perform differently in other populations. Simulation or replication of this analysis in a diverse set of populations could help elucidate the performance of UVL adjustment in different settings. Finally, poor specimen quality could have resulted in false-negative results for both the viral load and ARV biomarkers considered here. In spite of these limitations, this analysis does strongly suggest that use of UVL to adjust self-reported HIV status and ART use should be considered, especially in surveys where the inclusion of the ARV biomarker may be cost-prohibitive or subject to delays.

Conclusion

Undetectable viral load may be a useful biomarker for adjusting self-reported indicators of HIV diagnosis and treatment in cross-sectional surveys in absence of, or in addition to, adjustment based on detected ARVs in blood. Since viral load testing is routinely available within countries which are conducting HIV surveys and is relatively inexpensive due to its widespread use, it is a widely accessible measure which may be suitable for use in population-based surveys if ARV testing is unavailable or cost-prohibitive.

Competing interests

All authors declare no competing interests.

Authors' contributions

PWY, EZG and KDC conceived the study. PWY conducted the analyses. All authors contributed to drafting and critical review of the manuscript.

Acknowledgements

We would like to thank the University of Cape Town Department of Clinical Pharmacology for conducting the ART biomarker testing, the National HIV Reference Laboratory for conducting the KAIS 2012 viral load testing, the study teams that collected data in the field, and finally the survey participants.

Additional files

Additional file 1. Supplementary tables and figures

Word document containing additional supplementary analyses referenced in text.

References

1. National AIDS and STI Control Programme (NASCOP). 2007 Kenya AIDS Indicator Survey Final Report [Internet]. Nairobi, Kenya; 2009. Available from: http://stacks.cdc.gov/view/cdc/12122/

2. Waruiru W, Kim AA, Kimanga DO, Ng'ang'a J, Schwarcz S, Kimondo L, et al. The Kenya AIDS Indicator Survey 2012: rationale, methods, description of participants, and response rates. J Acquir Immune Defic Syndr [Internet]. 2014;66 Suppl 1:S3-12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24732819

3. Brown K, Williams DB, Kinchen S, Saito S, Radin E, Patel H, et al. Status of HIV Epidemic Control Among Adolescent Girls and Young Women Aged 15–24 Years — Seven African Countries, 2015–2017. MMWR. Morbidity and Mortality Weekly Report. 2018.

4. Bonnington O, Wamoyi J, Ddaaki W, Bukenya D, Ondenge K, Skovdal M, et al. Changing forms of HIV-related stigma along the HIV care and treatment continuum in sub-Saharan Africa: A temporal analysis. Sex Transm Infect. 2017;93:1–6.

5. Gurmu E, Etana D. HIV/AIDS knowledge and stigma among women of reproductive age in Ethiopia. African J AIDS Res. 2015;14(3):191–9.

6. Mooney AC, Campbell CK, Ratlhagana M-J, Grignon JS, Mazibuko S, Agnew E, et al. Beyond Social Desirability Bias: Investigating Inconsistencies in Self-Reported HIV Testing and Treatment Behaviors Among HIV-Positive Adults in North West Province, South Africa. AIDS Behav [Internet]. 2018;22(7):2368–79. Available from: https://doi.org/10.1007/s10461-018-2155-9

7. Kim AA, Mukui I, Young PW, Mirjahangir J, Mwanyumba S, Wamicwe J, et al. Undisclosed HIV infection and ART use in the Kenya AIDS indicator survey 2012: relevance to targets for HIV diagnosis and treatment in Kenya. AIDS [Internet]. 2016;30:2685–95. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00002030-900000000-97703

8. Huerga H, Shiferie F, Grebe E, Giuliani R, Farhat J Ben, Van-Cutsem G, et al. A comparison of self-report and antiretroviral detection to inform estimates of antiretroviral therapy coverage, viral load suppression and HIV incidence in Kwazulu-Natal, South Africa. BMC Infect Dis [Internet]. 2017;17(1):1–8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623964/

9. Koal T, Burhenne H, Römling R, Svoboda M, Resch K, Kaever V. Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom [Internet]. 2005 Nov 15;19(21):2995–3001. Available from: http://doi.wiley.com/10.1002/rcm.2158

10. Malm M, Römsing S, Obua C, Bergqvist Y. Determination of lamivudine, zidovudine, and nevirapine in capillary blood sampled on filter paper by LC. J Chromatogr Sci [Internet]. 2009;47(10):855–862. Available from: http://chromsci.oxfordjournals.org/content/47/10/855.short

11. World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva, Switzerland; 2016.

12. UNAIDS. Global AIDS Monitoring 2018: Indicators for monitoring the 2016 United Nations Political Declaration on Ending AIDS [Internet]. Geneva, Switzerland; 2017. Available from: https://www.unaids.org/sites/default/files/media_asset/2017-Global-AIDS-Monitoring_en.pdf

13. Barnabas R V., Revill P, Tan N, Phillips A. Cost-effectiveness of routine viral load monitoring in low- and middle-income countries: A systematic review. J Int AIDS Soc [Internet]. 2017;20(s7):e25006. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978710/

14. Zeh C, Ndiege K, Inzaule S, Achieng R, Williamson J, Chang JCW, et al. Evaluation of the performance of Abbott m2000 and Roche COBAS Ampliprep/COBAS Taqman assays for HIV-1 viral load determination using dried blood spots and dried plasma spots in Kenya. PLoS One. 2017;

15. Gonzalo-Gil E, Ikediobi U, Sutton RE. Mechanisms of virologic control and clinical characteristics of HIV+

elite/viremic controllers. Yale J Biol Med [Internet]. 2017;90:245–59. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482301/pdf/yjbm_90_2_245.pdf

16. Kayongo A, Gonzalo-Gil E, Gümüşgöz E, Niwaha AJ, Semitala F, Kalyesubula R, et al. Identification of Elite and Viremic Controllers from a Large Urban HIV Ambulatory Center in Kampala, Uganda. JAIDS J Acquir Immune Defic Syndr [Internet]. 2018;79(3):394–8. Available from: https://journals.lww.com/jaids/fulltext/2018/11010/Brief_Report___Identification_of_Elite_and_Viremic.16.aspx

17. Kiros Y, Elinav H, Gebreyesus A, Gebremeskel H, Azar J, Chemtob D, et al. Identification and characterization of HIV positive Ethiopian elite controllers in both Africa and Israel. HIV Med [Internet]. 2018;1–5. Available from: http://doi.wiley.com/10.1111/hiv.12680

18. Jain V, Liegler T, Kabami J, Chamie G, Clark TD, Black D, et al. Assessment of Population-Based HIV RNA Levels in a Rural East African Setting Using a Fingerprick-Based Blood Collection Method. Clin Infect Dis. 2013;56(4):598–605.

19. National AIDS and STI Control Programme (NASCOP). National Guidelines for HIV Testing and Counseling in Kenya. 2nd ed. Nairobi, Kenya; 2010.

20. Moyo S, Young PW, Gouws E, Naidoo I, Wamicwe J, Mukui I, et al. Equity of antiretroviral treatment use in high HIV burden countries : Analyses of data from nationally-representative surveys in Kenya and South Africa. PLoS One [Internet]. 2018;13(8):1–17. Available from: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0201899

21. National AIDS and STI Control Programme (NASCOP). Guidelines for antiretroviral therapy in Kenya, 4th Edition 2011 [Internet]. Kenya: National AIDS and STI Control Programme; 2011. Available from: http://www.emtct-iatt.org/wp-content/uploads/2013/04/Kenya_National-ARV-Guidelines_2011.pdf

22. UNAIDS. Fast-track: ending the AIDS epidemic by 2030. Geneva, Switzerland; 2014.

23. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2018. Available from: https://www.r-project.org/

24. Lumley T. survey: analysis of complex survey samples. 2017.

25. Li JZ, Etemad B, Ahmed H, Aga E, Bosch RJ, Mellors JW, et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS. 2016;30(3):343–53.

26. Jackson A, Moyle G, Watson V, Tjia J, Ammara A, Back D, et al. Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: Implications for HIV treatment and prevention. J Acquir Immune Defic Syndr. 2013;

27. Malawi Ministry of Health. Malawi Population-Based HIV Impact Assessment (MPHIA) 2015-2016: Final Report. Lilongwe; 2018.

Table 1. Self-reported HIV status and antiretroviral treatment (ART) use, KAIS 2012

Characteristic	Unaware n (%)	Aware, not on ART n (%)	Aware, on ART n (%)	N
Gender				
Male	120 (62.0)	22 (11.0)	51 (27.0)	193
Female	223 (47.8)	78 (17.5)	154 (34.7)	455
Age				
15-24 yrs	59 (82.0)	10 (10.9)	6 (7.1)	75
25-34 yrs	121 (58.9)	40 (20.0)	48 (21.1)	209
35-49 yrs	120 (44.1)	40 (14.8)	104 (41.1)	264
50-64 yrs	43 (43.1)	10 (8.9)	47 (48.0)	100
Marital status				
Single/never married	67 (73.5)	10 (9.8)	16 (16.7)	93
Married / cohabitating	210 (54.2)	57 (14.4)	118 (31.4)	385
Divorced / sep / widowed	66 (38.9)	33 (19.7)	71 (41.5)	170
Highest educational attainment				
None	49 (53.9)	12 (12.9)	28 (33.2)	89
Primary	192 (55.8)	60 (17.5)	94 (26.7)	346
Secondary	18 (57.4)	3 (11.2)	10 (31.4)	31
Higher	83 (47.4)	25 (11.9)	73 (40.8)	181
Employment				
Unemployed	124 (49.1)	33 (14.7)	82 (36.2)	239
Employed	218 (55.1)	67 (15.3)	123 (29.6)	408
Mobility				
Not away for >1 month in last year	196 (54.6)	52 (14.2)	112 (31.2)	360
Away >1 month in last year	131 (51.4)	45 (16.6)	87 (32.1)	263
ARV biomarker				
Present	55 (25.2)	12 (4.5)	168 (70.4)	235
Absent	233 (72.3)	73 (22.3)	18 (5.4)	324
UVL biomarker				
Present	65 (28.7)	25 (9.9)	145 (61.3)	235
Absent	253 (66.5)	74 (19.2)	55 (14.3)	382
Total	343 (53.1)	100 (15.1)	205 (31.8)	648

Note: ARV biomarker: test for presence of antiretrovirals in blood, UVL biomarker: present if respondent had undetectable viral load (<550 copies/mL) in blood. Missing values: one respondent was missing education and employment status, respectively, while 89 respondents were missing the ARV biomarker and 31 were missing viral load measure. Percentages are weighted to account for survey design.

Table 2. Self-reported and adjusted estimates of ART coverage among people living with HIV, KAIS 2012

	Self-reported			ARV only			Self-report or ARV			Self-report or UVL			Self-reported, ARV or UVL		
Characteristic	n	%	se	N	%	se	N	%	se	N	%	se	N	%	se
Sex															
Male	51	27.0	3.7	64	37.8	4.7	74	39.9	4.5	78	41.9	4.4	84	44.3	4.5
Female	154	34.7	2.5	171	45.6	2.6	198	44.6	2.5	217	48.8	2.5	230	51.6	2.5
Age group															
15–24 yrs	6	7.1	2.7	11	21.6	6.4	14	20.7	5.8	19	28.8	6.2	20	29.9	6.2
25–34 yrs	48	21.1	3.1	50	25.1	3.6	65	29.3	3.5	65	28.2	3.3	76	33.9	3.6
35–49 yrs	104	41.1	3.9	121	55.0	3.8	133	52.9	3.6	147	58.2	3.4	152	59.5	3.3
50–64 yrs	47	48.0	5.4	53	59.6	5.6	60	60.6	5.3	64	64.0	5.0	66	65.5	5.0
Marital status															
Single/never married	16	16.7	4.0	18	24.5	5.9	22	23.8	5.1	29	32.5	5.6	31	33.9	5.7
Married/cohabitating	118	31.4	3.2	141	42.0	3.4	163	43.3	3.2	175	46.1	3.1	186	48.6	3.2
Divorced /sep / widowed	71	41.5	4.0	76	53.1	4.3	87	52.6	4.0	91	54.2	3.9	97	58.1	4.0
Highest educational attainment															
None	28	33.2	5.8	31	35.5	5.9	39	44.6	6.0	39	45.2	6.0	41	46.5	6.0
Primary	94	26.7	2.8	111	39.5	3.6	126	38.4	3.3	137	40.8	3.3	148	44.3	3.5
Secondary	10	31.4	10.2	14	45.7	10.1	15	43.7	9.8	16	50.7	9.3	18	54.9	9.6
Higher	73	40.8	4.3	78	50.6	5.0	91	50.2	4.4	102	55.8	4.2	106	57.2	4.1
Employment															
unemployed	82	36.2	4.3	91	50.0	4.6	106	47.6	4.3	114	50.6	4.3	118	52.2	4.2
employed	123	29.6	2.6	144	39.0	2.8	166	40.5	2.8	181	44.0	2.7	196	47.2	2.8
Mobility															
Not away for >1 month in last year	112	31.2	3.0	126	42.0	3.5	146	42.2	3.2	156	44.5	3.3	166	46.8	3.2
Away >1 month in last year	87	32.1	3.4	101	43.7	4.0	117	43.7	3.6	129	48.0	3.7	137	51.4	3.9
Total	205	31.8	2.4	235	42.5	2.6	272	42.8	2.5	295	46.2	2.5	314	48.8	2.5

Note: self-reported: self-report only, ARV-only: based on presence/absence of ARVs only, self-report or ARV: either self-reported known-positive/on ART or ARVs detected, self-report or UVL: either self-reported known-positive/on ART or viral load was undetectable, self-report, ARV or UVL: either self-reported known-positive/on ART, ARVs detected, or UVL, se: standard error. Missing biomarker results were treated as biomarker not present. Percentages and standard errors are weighted and adjusted to account for the survey design.

Table 3. Self-reported and adjusted estimates of HIV care cascade, KAIS 2012

Characteristic		Self-report			Self-report or ARV			Self-report or UVL			Self-report, ARV or UVL		
Variable	Level	n	%	se	n	%	se	n	%	se	n	%	se
Awareness of HIV infection (1st 90)													
Gender	Male	73	38.0	4.3	92	49.5	4.9	95	50.7	4.9	99	52.6	5.0
	Female	232	52.2	2.8	268	60.4	2.6	275	61.7	2.5	286	64.2	2.5
Age group	15–24 yrs	16	18.0	5.0	24	31.7	6.5	27	37.7	7.0	28	38.8	7.0
	25–34 yrs	88	41.1	4.3	102	48.2	4.3	102	46.7	4.3	111	52.0	4.3
	35–49 yrs	144	55.9	3.8	167	65.7	3.4	172	67.6	3.3	176	68.5	3.3
	50–64 yrs	57	56.9	5.5	67	66.4	5.2	69	68.0	5.0	70	68.7	5.0
Total		305	46.9	2.8	360	56.2	2.8	370	57.5	2.8	385	59.8	2.8
ART coverage among previously-diagnosed (2nd 90)													
Gender	Male	51	71.0	5.8	74	80.7	4.5	78	82.5	4.0	84	84.2	3.9
	Female	154	66.4	3.3	198	73.9	3.0	217	79.1	2.7	230	80.4	2.6
Age group	15–24 yrs	6	39.3	10.4	14	65.5	10.0	19	76.3	7.3	20	77.0	7.1
	25–34 yrs	48	51.2	5.8	65	60.9	5.3	65	60.3	5.3	76	65.2	5.1
	35–49 yrs	104	73.6	4.4	133	80.5	3.7	147	86.2	2.7	152	86.8	2.6
	50–64 yrs	47	84.3	5.2	60	91.3	3.8	64	94.1	2.7	66	95.5	2.3
Total		205	67.9	3.2	272	76.2	2.8	295	80.2	2.3	314	81.7	2.3
Viral load < 1000 copies/mL among those on ART (3rd 90)													
Gender	Male	35	72.8	6.3	52	75.9	5.1	62	82.5	4.3	62	78.4	4.6
	Female	115	76.6	3.8	146	75.4	3.5	178	83.5	2.8	178	78.8	2.9
Age group	15–24 yrs	2	34.6	19.8	9	72.4	11.3	15	83.9	7.4	15	80.8	7.9
	25–34 yrs	29	57.3	8.2	35	50.0	7.3	46	68.4	6.7	46	57.0	6.6
	35–49 yrs	84	84.5	3.8	108	85.6	3.3	127	89.1	2.7	127	87.2	2.9
	50–64 yrs	35	74.9	6.6	46	77.5	5.7	52	81.2	5.2	52	79.2	5.3

Total	150	75.4	3.3	198	75.6	2.8	240	83.1	2.3	240	78.6	2.5

Note: self-reported: self-report only, self-report or ARV: either self-reported known-positive/on ART or ARVs detected, self-report or UVL: either self-reported known-positive/on ART or viral load was undetectable, self-report, ARV or UVL: either self-reported known-positive/on ART, ARVs detected, or UVL, se: standard error, viral suppression defined as <1000 copies/mL. Missing biomarker results were treated as biomarker not present. Percentages and standard errors are weighted and adjusted to account for the survey design.

Table 4. Measures of diagnostic accuracy for self-reported knowledge of HIV infection adjusted for UVL (index test) compared to self-reported status adjusted for ARV biomarker (reference standard), KAIS 2012

Self-reported knowledge of HIV infection adjusted for VL biomarker (index test)	**Self-reported knowledge of HIV infection adjusted for ARV biomarker (reference standard)**		
	Aware	**Unaware**	**Total**
Aware	345	25	370
Unaware	15	263	278
Total	360	288	648
Measure of Accuracy	Percentage (95% confidence interval)		
Sensitivity	95.8% (93.2–97.5)		
Specificity	91.3% (87.4–94.1)		
Positive predictive value	93.2% (90.2–95.4)		
Negative predictive value	94.6% (91.3–96.7)		

Notes: For consistency with previous analyses, missing values were treated as absence of confirmation for this analysis. A total of 2 respondents who were missing self-reported HIV status were classified as unaware, 89 respondents missing the ARV biomarker were classified as not having the biomarker present, and 31 respondents missing the viral load biomarker were classified as not having undetectable viral load. Percentages and Wilson score confidence intervals are unweighted.

Table 5. Measures of diagnostic accuracy for self-reported ART status adjusted for UVL (index test) compared to self-reported ART status adjusted for ARV biomarker (reference standard), KAIS 2012

Self-reported ART status adjusted for VL biomarker (index test)	**Self-reported ART status adjusted for ARV biomarker (reference standard)**		
	On ART	**Not on ART**	**Total**
On ART	253	42	295
Not on ART	19	334	353
Total	272	376	648
Measure of Accuracy	Percentage (95% confidence interval)		
Sensitivity	93.0% (89.3–95.4)		
Specificity	88.8% (85.2–91.6)		
Positive predictive value	85.8% (81.3–89.3)		
Negative predictive value	94.6% (91.7–96.5)		

Notes: For consistency with previous analyses, missing values were treated as absence of confirmation for this analysis. A total of 2 respondents who were missing self-reported HIV status were classified as not being on ART by self-report, 89 respondents missing the ARV biomarker were classified as not having the biomarker present, and 31 respondents missing the viral load biomarker were classified as not having undetectable viral load. Percentages and Wilson score confidence intervals are unweighted.

Figure 1. HIV cascade and ART coverage indicators, KAIS 2012



Notes: self-reported: self-report only, self or ARV: either self-reported known-positive/on ART or ARVs detected, self or UVL: either self-reported known-positive/on ART or viral load was undetectable, self-report, ARV or UVL: either self-reported known-positive/on ART, ARVs detected or UVL, 1st 90: UNAIDS 90-90-90 Fast-Track target of 90% of people living with HIV knowing their HIV-positive status, 2nd 90: 90% of those who know their status on ART, and 3rd 90: 90% of those on treatment with viral load < 1000 copies/mL.